Table 2

Relationship between TNM staging and EGFR families expressing in 111 cases of oral SCCS

TNMNo. of cases (%)Level of expressiona
EGFRC-erb B-2C-erb B-3C-erb B-4
+++/+++/−+++/+++/−+++/+++/−+++/+++/−
Tumor size
 T160 (54.05)19 (17.11)41 (36.94)22 (19.82)38 (34.23)18 (16.22)42 (37.84)31 (27.93)29 (26.13)
 T2–351 (45.95)22 (19.82)29 (26.12)18 (16.22)33 (29.73)27 (15.32)34 (30.63)24 (21.62)27 (24.32)
 PsbP >0.21P >0.88P >0.87P >0.63
Nodal stage
 N076 (68.47)18 (18.92)55 (49.55)22 (19.83)54 (48.65)17 (15.31)59 (53.15)33 (29.73)43 (38.74)
 N1–335 (31.53)20 (18.01)15 (13.51)18 (16.22)17 (15.32)18 (16.22)17 (15.32)22 (11.81)13 (11.71)
 PsP <0.003P <0.022P <0.002P >0.06
Metastasis
 M096 (86.49)31 (27.93)65 (58.56)29 (26.13)67 (60.36)24 (21.62)72 (64.87)43 (38.74)53 (47.75)
 M115 (13.51)10 (9.01)5 (4.51)11 (9.91)4 (3.60)11 (9.91)4 (3.60)12 (10.81)3 (2.70)
 PsP <0.001P <0.001P <0.001P <0.001
Total111 (100)42 (36.94)70 (63.06)40 (36.04)71 (63.96)35 (31.53)76 (68.47)55 (49.55)56 (50.45)
  • a No. of cases (%).

  • b Ps were calculated by the Fisher’s exact test.